What changed
$MKC — BUY 📊 | 6 MONTHS THESIS
🧭 Conviction: MED
🎯 FQ2 FY2026 (ends May) | reported Jun 25 | Rev $1.9B | EPS $0.80 vs $0.69 🟢 | Margin 14.3%
💡 Consensus was anchored to $0.69 EPS and muted growth; the 15.9% beat reveals both top-line acceleration and operating leverage. The Street still prices MKC as a no-growth utility at 16x P/E, while the actual run-rate supports above-sector-average growth and a 20–22x multiple.
📉 Reward/risk: 2.6:1
🏢 Business Quality: 7 — Leading branded spices/flavorings with 40% gross margins, 14.3% operating margin, and pricing power, but carries high net debt ($4.6B) and competitive pressures./10
📊 Valuation: cheap — Trailing adj. P/E 16.0x vs. Consumer Staples peers at 20–22x; EV/EBITDA ~13x; FCF yield ~6.5% (est.).
🔮 Catalyst: Sustained earnings momentum and sector rotation into defensives; next earnings report could raise FY2027 guidance.
💰 Entry: $51.05, stop $46.0, target $64.0
⚖️ Buy MKC: strong EPS beat and 16x P/E for a Consumer Staples name